Viewing data from:

DOXAZOSIN MESYLATE

ANDA

DOXAZOSIN MESYLATE | A212727 | RISING PHARMA HOLDINGS INC

4 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: CARDURA(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 4 NDCs

Highest NADAC/Unit

$0.1070

per ea

Lowest NADAC/Unit

$0.0671

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
16571016801DOXAZOSIN MESYLATE 8 MG TAB	$0.1070	EA	Generic	—	2026-06-17
16571016701DOXAZOSIN MESYLATE 4 MG TAB	$0.0911	EA	Generic	—	2026-06-17
16571016501DOXAZOSIN MESYLATE 1 MG TAB	$0.0763	EA	Generic	—	2026-06-17
16571016601DOXAZOSIN MESYLATE 2 MG TAB	$0.0671	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain6 active DMFs8 inactive

6 active API suppliers hold Drug Master Files for this ingredient.

EXCELLA GMBH AND CO KGDOXAZOSIN MESYLATE

DMF 126341997

DR REDDYS LABORATORIES LTDDOXAZOSIN MESYLATE USP

DMF 127501997

APOTEX PHARMACHEM INDIA PVT LTDDOXAZOSIN MESYLATE USP

DMF 130391998

APITORIA PHARMA PRIVATE LTDDOXAZOSIN MESYLATE USP (NON-STERILE DRUG SUBSTANCE)

DMF 199592006

COHANCE LIFESCIENCES LTDDOXAZOSIN MESYLATE USP

DMF 229412009

UNICHEM LABORATORIES LTDDOXAZOSIN MESYLATE USP

DMF 323752018

CIPLA LTDInactiveDOXAZOSIN MESYLATE

DMF 127841997

BASF PHARMACHEMIKALIEN GMBH CO KGInactiveDOXAZOSIN MESYLATE

DMF 138071998

CILAG AGInactiveDOXAZOSIN MESYLATE

DMF 141731999

PHARMACEUTICAL FINE CHEMICALS PFC BAHAMAS LTDInactiveDOXAZOSIN MESYLATE

DMF 142811999

MEDICHEM SAInactiveDOXAZOSIN MESYLATE

DMF 143661999

WOCKHARDT LTDInactiveDOXAZOSIN MESYLATE

DMF 152402001

CHONGQING BIOCARE PHARMACEUTICAL CO LTDInactiveDOXAZOSIN MESYLATE USP

DMF 206642007

STANDARD CHEM AND PHARM CO LTDInactiveDOXAZOSIN MESYLATE

DMF 207702007

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (4)

Sort:

#001 — EQ 1MG BASE

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Mar 15, 2022

No patent or exclusivity listings for this strength.

#002 — EQ 2MG BASE

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Mar 15, 2022

#003 — EQ 4MG BASE

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Mar 15, 2022

#004 — EQ 8MG BASE

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Mar 15, 2022